Oryzon Genomics S.A. Stock price

Equities

ORY

ES0167733015

Biotechnology & Medical Research

Delayed BME 12:35:12 2024-03-28 pm EDT 5-day change 1st Jan Change
1.718 EUR +0.47% Intraday chart for Oryzon Genomics S.A. -2.50% -9.00%
Sales 2023 - Sales 2024 * - Capitalization 98.98M 107M
Net income 2023 -3M -3.23M Net income 2024 * -5M -5.39M EV / Sales 2023 -
Net Debt 2023 * 7.32M 7.89M Net Debt 2024 * 19.1M 20.58M EV / Sales 2024 * -
P/E ratio 2023
-34.1 x
P/E ratio 2024 *
-14.9 x
Employees 44
Yield 2023 *
-
Yield 2024 *
-
Free-Float 83.55%
More Fundamentals * Assessed data
Dynamic Chart
Oryzon Genomics S.A. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Oryzon Genomics, S.A. Announces Topline Results from Phase IIb Portico Study of Vafidemstat in Borderline Personality Disorder CI
Oryzon Genomics S.A. announced that it expects to receive ?45 million in funding from Nice & Green SA CI
Oryzon Completes Patient Testing in Mid-stage Study of Borderline Personality Disorder Drug MT
Oryzon Genomics, S.A. Announces Last Patient Last Visit in Its Phase IIb Portico Study for Borderline Personality Disorder CI
Oryzon Genomics S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Oryzon Genomics, S.A. Presents Blinded Aggregated Safety Data from Vafidemstat's Ongoing Phase IIB Portico Trial in Borderline Personal Disorder CI
Oryzon Genomics S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Oryzon Genomics, S.A. Reports New Preliminary Blinded Aggregate Safety Data from Its Ongoing Phase IIb Portico Trial CI
Oryzon Genomics, S.A. Presents Positive Preclinical Data of Ory-4001 for the Treatment of Charcot-Marie-Tooth Disease Presented At the 2023 Peripheral Nerve Society Annual Meeting CI
Oryzon Genomics, S.A. to Present Positive Preclinical Efficacy Data of ORY-4001 in Charcot-Marie-Tooth Disease At the 2023 Peripheral Nerve Society Annual Meeting CI
Oryzon Genomics S.A. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Oryzon Genomics, S.A. Announces Positive Results from Planned Interim Analysis of PORTICO, a Phase 2b Adaptive Trial in Borderline Personality Disorder CI
Oryzon Announces First Patient in Frida, A Phase Ib Trial with Iadademstat in Relapsed Refractory Flt3-Mutant Acute Myeloid Leukemia Patients CI
Oryzon Genomics, S.A. Announces Clinical Candidate Nomination of ORY-4001 for the Treatment of CNS Disorders CI
More news
1 day+0.47%
1 week-2.50%
Current month-7.34%
1 month-8.03%
3 months-12.35%
6 months-15.78%
Current year-9.00%
More quotes
1 week
1.71
Extreme 1.708
1.78
1 month
1.55
Extreme 1.552
1.89
Current year
1.55
Extreme 1.552
2.39
1 year
1.55
Extreme 1.552
2.43
3 years
1.55
Extreme 1.552
4.10
5 years
1.48
Extreme 1.476
4.47
10 years
1.48
Extreme 1.476
5.25
More quotes
Managers TitleAgeSince
Founder - 00-06-01
Chief Executive Officer - 00-06-01
Director of Finance/CFO - 11-04-30
Members of the board TitleAgeSince
Director/Board Member 62 15-11-02
Chief Executive Officer - 00-06-01
Founder - 00-06-01
More insiders
Date Price Change Volume
24-03-28 1.718 +0.47% 13,834
24-03-27 1.71 0.00% 37,495
24-03-26 1.71 -1.04% 36,599
24-03-25 1.728 -1.82% 66,161
24-03-22 1.76 -0.11% 33,086

Delayed Quote BME, March 28, 2024 at 12:35 pm EDT

More quotes
Oryzon Genomics SA, is a Spain-based clinical phase biopharmaceutical company, which discovers and develops drugs based on epigenetics for the treatment of oncological and neurological diseases. Its compounds in clinical development include iadademstat (ORY-lOOl), an LSD1 inhibitor that is in Phase II trials for the treatment of acute myeloid leukemia and small cell lung cancer; and vafidemstat (ORY-2001), an LSD1 inhibitor optimized for the Central Nervous System (CNS), in multiple Phase II clinical trials for the treatment of CNS and psychiatric illnesses. The Company also has ORY-3001, in preclinical development for the treatment of non-oncological diseases and has additional programs to develop inhibitors against other epigenetic targets.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.718 EUR
Average target price
6.843 EUR
Spread / Average Target
+298.31%
Consensus
  1. Stock
  2. Equities
  3. Stock Oryzon Genomics S.A. - BME